STAT+: Ultragenyx cuts staff after another study fails

Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Every article behind this summary — 1 article from 1 outlet